Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | MVD | P53602 | 2/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28609025 | 0.98 | CA12 (0.39) | CA12CA1CA2CA9MVD | |
| SCHEMBL28587893 | 0.90 | CA12 (0.41) | CA12CA1CA2CA9MVD | |
| SCHEMBL19206446 | 0.87 | LPAR3 (0.35) | CA12CA1CA2CA9MVD | |
| SCHEMBL14086322 | 0.85 | CA12 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL15634387 | 0.83 | CA12 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL25821319 | 0.83 | CA12 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL17036885 | 0.81 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL15833170 | 0.81 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL26297735 | 0.80 | CA12 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL13656413 | 0.80 | CA12 (0.38) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107148423-B | Thionucleoside derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2021-07-30 | — | — | CN | claimed |
| CN-107148423-B | Thionucleoside derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2021-07-30 | — | — | CN | disclosed |
| US-7468357-B2 | Nucleosides with anti-hepatitis B virus activity | EMORY UNIVERSITY (US) | 2008-12-23 | — | — | US | disclosed |
| EP-0831852-B1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | UNIV EMORY (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1655033-A1 | Nucleosides with anti-hepatitis B virus activity | Emory University (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20020107221-A1 | Nucleosides with anti-hepatitis B virus activity | SCHINAZI RAYMOND F (US) | 2002-08-08 | — | — | US | disclosed |
| US-6245749-B1 | TIME-RELEASE INJECTION OF 2*,3*-DIDEOXYADENOSINE | EMORY UNIVERSITY | 2001-06-12 | — | — | US | disclosed |
| EP-0831852-A1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040164-A1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107221-A1 | Nucleosides with anti-hepatitis B virus activity | PNP, ADA, TYMP | CA12 4491/4885CA1 4617/4885CA2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.